HadosLab Blog
Peptides, the chemical language of life
Peptides are the molecules the body uses to talk to itself. Short chains of amino acids that regulate sleep, tissue regeneration, appetite or cellular aging. In the last decade they have gone from being a laboratory curiosity to becoming one of the most dynamic fields in biotechnology: drugs such as semaglutide or tirzepatide, both peptides, already move tens of billions of euros a year and have changed the way obesity and diabetes are treated.
Behind that pharmaceutical revolution lies another, quieter one, taking place in research laboratories, longevity programs and startups that combine artificial intelligence with protein chemistry. Understanding what a peptide is, and what it is not, has become essential for anyone closely following biohacking, regenerative medicine or the next generation of targeted therapies.
This article aims to serve as a map. What peptides are, how they work, what is being researched, why compound purity matters so much, and where exactly their regulation stands in Europe and the United States in 2026.
What exactly is a peptide
A peptide is a short chain of amino acids linked by peptide bonds, a specific type of amide bond formed when the carboxyl group (-COOH) of one amino acid reacts with the amino group (-NH2) of the next, releasing a water molecule in the process. That bond, rigid and planar by resonance, was described in the early 20th century and is the structural basis of all known life.
The boundary between peptide, polypeptide and protein is operational, not absolute. IUPAC, the international authority on chemical nomenclature, proposes these orientative ranges:
- Oligopeptide: fewer than 10-20 amino acids, such as di-, tri-, tetra- or pentapeptides.
- Polypeptide: chains of 10 to 50 residues, still without complex tertiary structure.
- Protein: polypeptides of more than 50 amino acids with defined three-dimensional folding.
The practical difference matters. A free amino acid, like leucine or glycine, has hardly any biological function on its own. A nine-residue peptide, on the other hand, can be oxytocin and trigger childbirth. A 51-residue protein can be insulin and regulate the glucose of the entire organism. Length marks complexity, but sequence marks function.
How peptides talk to cells
If DNA is the instruction manual and proteins are the machines that do the work, peptides are the messages. They circulate in the blood, travel between neurons or are released locally in a tissue and dock onto specific receptors on the surface of cells.
Most act on G-protein coupled receptors (GPCRs), a family of about 800 membrane proteins that constitute the target of around one third of all drugs approved worldwide. When a peptide fits its receptor, it triggers intracellular cascades, such as cAMP, MAPK, PI3K/Akt or calcium mobilization, which translate the chemical message into biological action: contracting a muscle, secreting insulin, activating a gene or initiating tissue repair.
Other peptides act on tyrosine kinase receptors, like the insulin receptor, on guanylate cyclase, like cardiac natriuretic peptides, or on JAK/STAT receptors, like growth hormone. The key is specificity: each peptide usually activates a very specific receptor, which makes them potentially cleaner therapeutic tools than traditional small molecules, capable of hitting several targets at once.
Natural, synthetic, pharmaceutical, cosmetic
Not all peptides are alike, and confusing categories is the source of most misunderstandings.
Endogenous peptides are those produced by the body itself: insulin, glucagon, oxytocin, vasopressin, GHRH, somatostatin, GLP-1, enkephalins, substance P or natriuretic peptides. They are synthesized in ribosomes from longer precursors that are then enzymatically trimmed.
Synthetic peptides are manufactured in the laboratory, normally through solid-phase synthesis (SPPS), a technique that revolutionized chemistry from 1963 onwards. They can be identical copies of human peptides or modified analogs: with D-amino acids, lipidation, PEGylation or cyclization to make them more stable.
In terms of use, three very different categories coexist:
- Approved pharmaceuticals: they have passed clinical trials and have authorization from the FDA, EMA or other agencies. Examples: semaglutide, insulin, teriparatide, octreotide, leuprorelin or desmopressin.
- Cosmetics: topical peptides included in creams and serums, regulated by Regulation (EC) 1223/2009 in the European Union. The best known are Matrixyl, Argireline and topical GHK-Cu.
- Research use only: compounds intended for exclusive use in the laboratory, not approved for human or veterinary consumption. This is the category in which BPC-157, TB-500, CJC-1295 or Epitalon operate.
From Emil Fischer to automated synthesis
The history of peptides is a succession of Nobel prizes. In 1901, the German chemist Emil Fischer synthesized the first dipeptide, glycyl-glycine, and coined the term peptide bond. By 1907 he had already produced an 18-amino-acid chain. Fischer received the Nobel Prize in Chemistry in 1902, founded peptide chemistry and proposed the lock-and-key model of enzymes.
Half a century later, in 1955, the British scientist Frederick Sanger published the complete sequence of insulin, 51 amino acids and three disulfide bridges, the first protein deciphered in atomic detail. That work demonstrated that proteins have a defined and reproducible sequence, not a random one. It earned him the Nobel Prize in 1958 and he would repeat in 1980 for sequencing DNA.
In 1953, Vincent du Vigneaud synthesized for the first time a complete peptide hormone: oxytocin. Two years later he received the Nobel Prize. And in 1963, Robert Bruce Merrifield published in the Journal of the American Chemical Society a technique that would change everything: solid-phase synthesis, or SPPS. It consists of anchoring the first amino acid to a resin bead and adding the following ones one by one, washing impurities between steps. Merrifield received the Nobel Prize in 1984 and his method, automated and refined, is the one used today in any serious laboratory in the world.
The approval of recombinant human insulin in 1982, the first biotechnological drug in history, opened the door to an entire generation of peptide drugs: leuprolide, octreotide, goserelin, teriparatide, exenatide and, in the following decade, the saga of GLP-1 agonists that today dominates the global pharmacy.
The current frontier: regeneration, longevity, recovery
Outside the approved pharmaceutical circuit, several peptides have become protagonists of preclinical research and an object of fascination for the biohacking community. They deserve to be mentioned with intellectual honesty: the available evidence is, in many cases, promising but incomplete.
BPC-157, the gastric pentadecapeptide
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid fragment derived from a protein present in human gastric juice. The bulk of the research comes from the group of Predrag Sikiric at the University of Zagreb, which since the 1990s has published studies in animal models on the healing of tendons, ligaments and gastrointestinal mucosa, with mechanisms related to angiogenesis and the nitric oxide pathway. Its Achilles' heel is the scarcity of clinical trials in humans: much of the available literature remains preclinical.
TB-500, fragment of thymosin beta-4
TB-500 is not the complete thymosin beta-4, a natural 43-amino-acid protein isolated in 1981, but a synthetic acetylated fragment of its N-terminal end. It acts on the dynamics of the actin cytoskeleton and has shown, in preclinical models, effects on cell migration, angiogenesis and tissue repair. It has been banned by the World Anti-Doping Agency since 2011.
GHK-Cu, the tripeptide with history
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper) is, probably, the peptide with the most solid scientific track record in this group. It was discovered by Loren Pickart in 1973 in human plasma. Its concentration drops from about 200 ng/mL at twenty years of age to about 80 ng/mL at sixty, which motivated much of the subsequent research. Various studies document its role in stimulating collagen, decorin and glycosaminoglycans, with antioxidant and anti-inflammatory effects. It is the active ingredient of multiple high-end cosmetic formulas.
Mitochondrial peptides and longevity
The most intriguing frontier, from the point of view of aging, are the mitochondrial peptides such as humanin or MOTS-c. Discovered in the last decade, they are encoded in mitochondrial DNA and seem to function as metabolic stress signals. A polymorphism of the MOTS-c gene has been associated with exceptional longevity in the Japanese population, and recent studies suggest a protective role against pancreatic cell senescence.
Why injectables and not pills
The question makes anyone starting to take an interest in peptides uncomfortable. The answer is biochemical, not arbitrary. The human digestive tract is designed precisely to destroy proteins and peptides: gastric pepsin, trypsin, chymotrypsin and brush border peptidases shred any amino acid chain before it can cross the intestinal epithelium.
To this is added the poor intestinal permeability of large polar molecules, the hepatic first-pass effect and an often very short plasma half-life. Endogenous GLP-1, for example, is degraded in just two minutes. The oral bioavailability of an unmodified peptide is typically below 1-2%.
The industry has sought ingenious workarounds. The best-known case is oral semaglutide (Rybelsus), approved by the FDA in 2019: it is co-formulated with SNAC, an absorption enhancer that creates an alkaline microenvironment in the stomach and allows the peptide to cross the gastric epithelium. Even so, its bioavailability is around 0.4-1%. Other strategies, such as lipidation, PEGylation, Aib substitutions, cyclization, intranasal, transdermal or microneedles, are pushing the oral route forward, but subcutaneous injection remains the standard for a very simple reason: it works, it is predictable and it respects the pharmacokinetics of the peptide.
Purity, HPLC and the COA: why not every peptide is the same peptide
Two vials with the same label can contain radically different products. The difference is not visible to the naked eye. It is seen in the laboratory.
The reference technique for evaluating purity is reverse-phase high-performance liquid chromatography (RP-HPLC), normally with a C18 column and UV detection at 214 nm. The result is a chromatogram in which the main peak of the peptide should stand out against an almost non-existent baseline noise. Alongside it, mass spectrometry (ESI-MS or MALDI-TOF) confirms that the observed molecular mass matches the theoretical one, that is, that the synthesized sequence is correct.
The document that records these analyses is called the Certificate of Analysis (COA) and ideally comes from an accredited ISO 17025 independent third-party laboratory. It must include: name and sequence of the peptide, batch number, HPLC chromatogram with purity percentage, theoretical and observed molecular mass, net peptide content, water content and, for sensitive applications, endotoxin and bioburden levels.
The usual standards are clear: 95% or more for preliminary research, 98% or more for rigorous trials and 99% or more for in vivo studies or mechanistic publications. Any compound without a traceable and verifiable COA cannot be considered a serious research peptide.
The regulatory maze in 2026
This is, perhaps, the most changing and worst understood point in the peptide ecosystem. In 2026, regulation on both sides of the Atlantic is going through an unusually active moment.
In the United States, the FDA classified in September 2023 around nineteen popular peptides, such as BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, injectable GHK-Cu, melanotan II, MOTS-c or epitalon, in Category 2 of bulk substances, which restricted their preparation in compounding pharmacies. In February 2026, after regulatory and legal pressure, the Secretary of Health announced that fourteen of them would be reclassified to Category 1. On 15 April 2026, the FDA formally published the removal of twelve peptides from the list of significant concerns. Advisory committees scheduled meetings in July 2026 for the formal evaluation of BPC-157, TB-500, MOTS-c and DSIP, among others.
In Europe and Spain, the picture is very different. There is no equivalent to the American 503A/503B compounding system. Any substance with pharmacological properties intended for human use requires marketing authorization from the EMA or the AEMPS. Experimental peptides such as BPC-157 are not authorized for human use in any European Union country. Their sale implying human therapeutic use constitutes the marketing of an unauthorized medicinal product.
The research use only category covers B2B sales to laboratories under the REACH and CLP regulations, with explicit labeling for laboratory use only, not for human or veterinary consumption. That label is not a legal shield nor a quality standard: it is a delimitation of use. It indicates that the product is intended for scientific research, not self-administration. Any commercial promotion implying human use automatically activates pharmaceutical legislation.
The World Anti-Doping Agency (WADA) maintains in its 2026 list the prohibition of BPC-157 in the S0 category and of peptide growth factor analogs in S2, both in and out of competition.
The future: peptides designed by artificial intelligence
The next decade of peptides is already being written in laboratories that combine chemistry and deep learning. Tools such as AlphaFold3 and RFdiffusion allow de novo design of peptides that bind to specific targets with affinities that sometimes exceed, by orders of magnitude, those of natural molecules.
In parallel, cyclic peptides and stapled peptides, chains stabilized with chemical bridges, are solving the old problem of fragility. Peptide-drug conjugates (PDC), such as Lutathera or Pluvicto, already bill more than one billion dollars a year carrying radioisotopes to specific tumors. And next-generation trials, such as Retatrutide or orforglipron, are aiming at weight losses of 25-30% and the normalization of metabolic profiles.
The global market for therapeutic peptides oscillates, depending on the consultancy, between 50 and 140 billion dollars in 2025, with annual growth projections of 5-11%. Beyond the exact figure, the trend is unequivocal: peptides are taking over territory that previously belonged to small molecules and monoclonal antibodies.
Conclusion
Peptides are not a shortcut. They are a mature scientific field, with more than a century of history and a trajectory marked by four Nobel prizes, that today is going through an unusually fast moment of expansion. Their strength lies in a combination difficult to replicate: biological specificity, potency at low doses and, when used appropriately, favorable safety profiles.
Separating noise from signal is, today more than ever, an individual responsibility. A peptide with a serious COA, produced with analytical rigor and intended for research, is not the same as a powder sold in a forum. Understanding the difference, between the approved and the experimental, between the preclinical and the clinical, between what marketing promises and what peer-reviewed literature supports, is the first act of intellectual hygiene of anyone approaching this field.
Peptide biotechnology is just beginning. What today seems like a frontier, in ten years will be standard medicine. And what today seems like a miracle, will probably not pass the trials. Distinguishing one from the other is the work.